Alvotech Launches Trading on Nasdaq Stockholm
As of today, Alvotech (NASDAQ: ALVO) announces an exhilarating milestone: trading of its shares on Nasdaq Stockholm has officially commenced. This listing marks a significant step forward for the global biotech company, which is widely recognized for developing and producing biosimilar medicines for patients around the globe.
The recent public offering of Swedish Depository Receipts (SDRs) was met with substantial enthusiasm, reflecting the robust interest from the general public in Sweden. In fact, the offering was oversubscribed multiple times, showcasing investors’ strong confidence in Alvotech's future and growth potential.
Highlights of the Offering
The final Offering Price was set at SEK 87.51 per SDR, which corresponds to the average market price of Alvotech’s ordinary shares on Nasdaq Iceland during the application period. This pricing included a ten percent discount and was established using the exchange rates published by Sweden's central bank. During the application window from May 9 to 16, 2025, an impressive 441,600 SDRs were offered, each representing one ordinary share of Alvotech. The gross proceeds totaled around SEK 39 million.
Moreover, all 3,000+ individuals who subscribed for SDRs in this offering were allotted shares, emphasizing the broad-based interest in Alvotech’s market entrance under the ticker symbol “ALVO SDB”. Settlement for these transactions is expected to occur shortly.
Alvotech's Vision and Market Expansion
According to Róbert Wessman, Alvotech’s Founder, Chairman, and CEO, this listing on Nasdaq Stockholm is pivotal, allowing the company to better service current and future shareholders. "Our aim is to enhance market accessibility for our investors in the Nordic and European territories. Today is a thrilling new chapter for Alvotech as our shares are now traded across three major markets," he stated. This development is anticipated to improve share liquidity and broaden the company’s shareholder base significantly.
The company is focused on advancing its research and development (R&D) capabilities. The expansion strategy includes attracting seasoned life-science R&D professionals from outside Iceland, which will bolster Alvotech’s innovative efforts. Notably, the acquisition of Xbrane Biopharma AB’s operations at a recognized life-science hub in Sweden is a key move in integrating additional talented developers into Alvotech's workforce, thereby enhancing its scientific capabilities.
Strengthening European Presence
With the listing on Nasdaq Stockholm, Alvotech aims to strengthen its visibility within the Nordic and European markets, all while enhancing access to essential regional capital. Their strategy includes engaging with institutional and retail investors across various markets to widens their investment base significantly. Growing investor demand in the European biotechnology sector presents a promising opportunity for the firm.
Additionally, Alvotech has recognized the necessity for liquidity improvements and plans to enter agreements with market makers to facilitate trading volume for its newly listed SDRs.
Special Conversion Opportunities for Shareholders
In a beneficial move for existing shareholders, Alvotech will offer a unique free conversion period. This initiative allows previous shareholders to convert their unrestricted shares into SDRs without conversion fees during the first year of trading. This step is aimed at increasing the shareholder engagement in capitalizing on the SDRs during their early trading days.
For more information about the conversion process, shareholders can contact Alvotech’s designated email.
The Future of Alvotech
As a dedicated player in the biotechnology sphere, Alvotech prides itself on fostering high-quality, affordable biosimilar medicines catering to unique health needs. Their current portfolio includes two approved biosimilars, with a pipeline comprising nine additional candidates targeting a range of medical conditions including autoimmune disorders and cancer.
With established partnerships including Teva Pharmaceuticals and other notable firms, Alvotech is well-positioned for an expansive market reach, thereby contributing to its goal of becoming a leading force in the biosimilars market globally.
Frequently Asked Questions
What is the significance of Alvotech's listing on Nasdaq Stockholm?
The listing enables Alvotech to tap into a broader investor base and enhances share liquidity, supporting its growth ambitions in the biosimilars sector.
What was the outcome of the recent SDR offering?
The SDR offering was oversubscribed and raised approximately SEK 39 million, showing strong public interest in Alvotech's future endeavors.
How does Alvotech plan to expand its R&D capabilities?
The company aims to integrate Xbrane Biopharma's R&D operations, enhancing its scientific expertise and broadening its talent pool.
What are Alvotech's current products in the market?
Alvotech has two approved biosimilars for Humira (adalimumab) and Stelara (ustekinumab), targeting multiple global markets.
Who can convert shares to SDRs, and what are the fees involved?
Existing shareholders can convert their unrestricted shares to SDRs during the one-year free conversion period, with conversion fees covered by Alvotech, except any additional custodian costs.
